RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding "Intimation about the approval received from Reserve Bank of India and Competition Commission of India in respect of the Scheme of Arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd".

Ranbaxy Laboratories Limited has informed the Exchange regarding Stock Exchange Statement dated January 27, 2015 which is being issued by the Company.

Ranbaxy Laboratories Limited has informed the Exchange vide Letter dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy s April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased with this verdict, and is committed

Ranbaxy Laboratories Limited has informed the Exchange regarding the Statement dated November 19, 2014. "Princeton, NJ; Gurgaon, India, November 19, 2014: Following, and in response to, the revocation of Ranbaxy s tentative approvals for Ranbaxy s ANDAs for esomeprazole magnesium delayed-release capsules and valganciclovir hydrochloride tablets, Ranbaxy has filed a complaint against the U.S. FDA in D.C. federal court and has also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy s case is decided."

Ranbaxy Laboratories Limited has informed the Exchange regarding the "Statement" dated November 6, 2014 "Ranbaxy Laboratories Limited (Ranbaxy) has received communication from the US FDA".

Ranbaxy Laboratories Limited has informed the Exchange that Company have received a letter on October 31, 2014 from the Luxembourg Stock Exchange (LSE) (where GDS of the Company are listed) intimating that in view of the termination of the Deposit Agreement on December 15, 2014, they will de-list the GDS from the official list of the LSE and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014.

Ranbaxy Laboratories Limited has informed the Exchange that the Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which it reports pricing data for certain products eligible for reimbursement under the Medicaid program. The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation. The Company would fully cooperate with this civil investigation.

Ranbaxy Laboratories Limited has informed the Exchange that the Company has received direction vide letter dated August 27, 2014 under Section 29(2) of the Competition Act, 2002 from the Competition Commission of India(CCI) directing the Company to publish the details of the proposed combination in the prescribed format within 10 working days from the date of the said letter of the CCI.

Ranbaxy Laboratories Limited has informed the Exchange that pursuant to Rule 20(3)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed June 20, 2014 as the relevant date to determine shareholders eligible to cast their votes electronically for transacting the items at the said AGM.

Ranbaxy Laboratories Limited has informed the Exchange that United States Attorney's Office for the District of New Jersey has issued an administrative subpoena dated March 13, 2014 to Ranbaxy seeking information primarily related to the Company's API Toansa manufacturing facility in India for which a Form 483 was issued by FDA culminating into import alert. The Toansa facility is subject to certain terms of Consent Decree entered against Ranbaxy in January 2012. The Company is fully cooperating with this information request. Ranbaxy is confident that its pharmaceutical products are safe and e

Ranbaxy Laboratories Limited has informed the Exchange that the Company is currently examining processes and controls at all Company's Active Pharmaceutical Ingredients (API) Manufacturing and Quality units. This action has led to temporarily putting on hold shipments from Company's API facilities of the Toansa and Dewas Plants.This voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the Company to assess and review the processes and controls. The Company will resume shipments after reassuring them about the processes and controls at these facili

Ranbaxy Laboratories Limited has informed the Exchange as per the provisions of the Company's Code for Prevention for Insider Trading, trading window will remain closed from January 24, 2014 to February 6, 2014 (both days inclusive) for the employees/directors of the Company.

Ranbaxy Laboratories Limited has informed the Exchange, vide letter dated September 17, 2013 regarding "Import Alert by USFDA".

Ranbaxy Laboratories Limited has informed the Exchange regarding " Decision of European Commission".

Ranbaxy Laboratories Limited has informed the Exchange regarding an update on Atorvastatin Recall, which is being issued by the Company on February 25, 2013.

Ranbaxy Laboratories Limited has informed the Exchange that the Company on November 23, 2012 has issued 5,000 Secured 9.20% Redeemable Non-Convertible Debentures of face value of Rs. 10,00,000/- each, for cash at par, aggregating Rs. 500 Crores, on a private placement basis, for general corporate purposes. These Debentures have been rated AA+ by CARE and are proposed to be listed on National Stock Exchange of India Ltd. (NSE).

Ranbaxy Laboratories Limited has informed the Exchange that the Company has made a recall of Atorvastatin from the USA market which will cause temporary disruption to that market of this product. The investigation with regard to the same of this issue is expected to be completed within two weeks and thereafter the Company expects to resume supplies.

Ranbaxy Laboratories Limited has informed the Exchange vide letter dated August 22, 2012 regarding "Development relating to withdrawal by Ranbaxy of 27 approved ANDAs in the USA market appearing on US Regulator website and on certain online portals".

Ranbaxy Laboratories Limited has informed the Exchange that the Company has fully redeemed US$440,000,000 Zero Coupon Convertible Bonds ("Bonds") on March 18, 2011 (being the maturity date of the Bonds).

Ranbaxy Laboratories Limited has informed the Exchange that Mr. Omesh Sethi, President & Chief Financial Officer has resigned from the services of the Company, with effect from January 25, 2011.

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has formulated its Medium Term Plan (MTP) for the period 2010-2012. As per the MTP, the Company aims to achieve global consolidated turnover of Three Billion US Dollars (approx. INR 140 billion) for the financial year ending December 2012.<a href=/content/corporate/Ranbaxy_Updt_12032010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a Statement dated December 24, 2009, which is being issued by Ohm Laboratories Inc., New Jersey, USA, a wholly owned subsidiary of the Company. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_st_24122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd had submitted to the Exchange a copy of "Notice of Change of Control" issued by the Company to the Trustees of Foreign Currency Convertible Bondholders. The Company has now informed the Exchange that: "Further to above, the RBI vide letter dated November 3, 2008 has rejected the application of the Company for early redemption of the Bonds. The Company has issued a communication dated November 4, 2008 to the Trustees of the Bondholders informing about the response of the RBI." The details of the same shall be available on the NSE website (http://www.nseindia.com) under:

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the "Notice of Change of Control" issued by the Company on October 24, 2008 to the Trustees of the Foreign Currency Convertible Bond holders in terms of the Offering Circular of the Bonds. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Up_27102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that M/s Daiichi Sankyo Company, Limited ("Daiichi Sankyo") having its Registered office at 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo-103-8426, Japan, has acquired 52.5% of the Issued, Subscribed and Fully Paid-up Equity Shares of Rs.5 each ("Shares") of Ranbaxy Laboratories Limited ("the Company") comprising 220,690,423 shares. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ran

Ranbaxy Laboratories Ltd has informed the Exchange that: "The U.S. Department of Justice has now been provided with a comprehensive set of audit documents based on instructions by Ranbaxy Laboratories Limited, which will help resolve the questions raised by the U.S. government about the company's business practices and standards. Ranbaxy remains confident that its Pharmaceutical products are safe and effective and remains committed to cooperatively working with all regulatory and legislative authorities".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 18, 2008, titled " Ranbaxy Laboratories Ltd., Retains former New York city Mayor Rudy Giuliani to lead team in resolution of issues raised by U.S. Food & Drug Administration". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18092008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of 'Ranbaxy, Statement on FDA Letters'. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Updates_17092008.zip target=NEW> For more details click here.</a>

ICICI Securities Limited has informed the Exchange regarding Public Offer for acquisition of 20% of Emerging Voting Capital of Ranbaxy Laboratories Limited by Daiichi Sankyo Company, Limited - Pursuant to Regulations 10 and 12 of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequentamendments thereto. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PO_0

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended June 30, 2008 (taken on record by the Board of Directors of the Company at its meeting held on July 29 2008) that: "Pursuant to the Announcements "Accounting for Derivatives" by the Institute of Chartered Accountants of India, the Company intends to go for an early adoption of Accounting Standard 30 on Financial Instruments: Recognition and Measurement ("AS 30") Pending adoption of AS 30 (when appropriate accounting would be carried out ), it is pertinent to disclo